JACC. Case reports · 2026
Novel Use of Mavacamten in RAF1-Associated Noonan Syndrome With Hypertrophic Cardiomyopathy.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ziauddin Lubna, Davidson Erin, Spears Hannah, Coffman Erin, McNutt Markey, Hendren Nicholas, Kearney Katherine, Hegde Sheila M, Grodin Justin L, Tapaskar Natalie
Аннотация
BACKGROUND: Mavacamten is a first-in class allosteric inhibitor of cardiac myosin that is shown to reduce left ventricular outflow tract obstruction and improves symptoms in obstructive hypertrophic cardiomyopathy (HCM). However, there have been limited studies of the use of mavacamten in nonsarcomeric forms of HCM, such as Noonan syndrome.
CASE SUMMARY: This case report describes therapeutic benefit with mavacamten in a 26-year-old man with RAF1-associated Noonan syndrome and previous septal myectomy.
DISCUSSION: This case represents one of the first reports of mavacamten use in RAF1-associated Noonan syndrome, a nonsarcomeric form of HCM, in a patient with recurrent obstruction after early septal myectomy. Treatment was associated with progressive reduction in left ventricular outflow tract gradients and symptomatic improvement, supporting myosin inhibition as a potential therapeutic strategy in syndromic HCM.
TAKE-HOME MESSAGE: Mavacamten may be an effective treatment for obstructive HCM from RAF1-associated Noonan syndrome.
CASE SUMMARY: This case report describes therapeutic benefit with mavacamten in a 26-year-old man with RAF1-associated Noonan syndrome and previous septal myectomy.
DISCUSSION: This case represents one of the first reports of mavacamten use in RAF1-associated Noonan syndrome, a nonsarcomeric form of HCM, in a patient with recurrent obstruction after early septal myectomy. Treatment was associated with progressive reduction in left ventricular outflow tract gradients and symptomatic improvement, supporting myosin inhibition as a potential therapeutic strategy in syndromic HCM.
TAKE-HOME MESSAGE: Mavacamten may be an effective treatment for obstructive HCM from RAF1-associated Noonan syndrome.